Establishment of an oral squamous cell carcinoma model by using chemical carcinogen 4-NQO

doi:10.19438/j.cjoms.2019.04.003

Abstract

Abstract: PURPOSE: To establish a murine model with oral squamous cell carcinoma（OSCC）induced by chemical carcinogen 4-NQO. Methods: 4-NQO was added to drinking water for C57BL/6 mice, and the changes of oral mucosa were observed. The mice were sacrificed at various time points (12, 16, 20, 24 weeks), and the tissue samples were collected for identifying the characteristics and primary cell culture. Results: Mice in the experimental group had obvious exogenous tumors in the oral mucosa after 16 weeks, their diameters were about 0.2 mm. H-E staining of the tumors showed exogenous or invasive growth, with obvious keratinization and mitosis. The cells were polygonal and adherent to the wall firmly. CK and ki-67 staining was positive, indicating that the cells were squamous cell carcinoma cells. Conclusions: The induction process of this model is similar to that of human OSCC development, and it is an ideal animal model to study the mechanism of OSCC.

Key words: Oral squamous cell carcinoma, 4-NQO, Animal model, Cell line

CLC Number:

R739.8

FU You, XU Ke, LI Jiang, SUN Shu-yang, ZHANG Zhi-yuan. Establishment of an oral squamous cell carcinoma model by using chemical carcinogen 4-NQO[J]. China Journal of Oral and Maxillofacial Surgery, 2019, 17(4): 300-303.

References

[1] De Moerlooze L, Spencer-Dene B, Revest JM, et al.An important role for the IIIb isoform of fibroblast growth factor receptor 2 (FGFR2) in mesenchymal-epithelial signalling during mouse organogenesis[J]. Development, 2000, 127(3): 483-492.
[2] Kang H, Kiess A, Chung CH.Emerging biomarkers in head and neck cancer in the era of genomics[J]. Nat Rev Clin Oncol, 2015, 12(1): 11-26.
[3] Bray F, Ferlay J, Soerjomataram I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424
[4] Gould SE, Junttila MR, de Sauvage FJ. Translational value of mouse models in oncology drug development[J]. Nat Med, 2015, 21(5): 431-439.
[5] de Visscher SA, Witjes MJ, van der Vegt B, et al. Localization of liposomal mTHPC formulations within normal epithelium, dysplastic tissue, and carcinoma of oral epithelium in the 4NQO-carcinogenesis rat model[J]. Lasers Surg Med, 2013, 45(10): 668-678.
[6] Miki K, Orita Y, Gion Y, et al.Tumor-associated macrophages in the development of 4-nitroquinoline-1-oxide-induced tongue squamous cell carcinoma in a mouse model[J]. Oncology, 2017, 93(3): 204-212.
[7] Young MR.Use of carcinogen-induced premalignant oral lesions in a dendritic cell-based vaccine to stimulate immune reactivity against both premalignant oral lesions and oral cancer[J]. J Immunother, 2008, 31(2): 148-156.
[8] Tseng SH, Yang CC, Yu EH, et al.K14-EGFP-miR-31 transgenic mice have high susceptibility to chemical-induced squamous cell tumorigenesis that is associating with Ku80 repression[J]. Int J Cancer, 2015, 136(6): 1263-1275.
[9] Miki K, Orita Y, Gion Y, et al.Regulatory T cells function at the early stage of tumor progression in a mouse model of tongue squamous cell carcinoma[J]. Cancer Immunol Immunother, 2016, 65(11): 1401-1410.
[10] Ohne M, Satoh T, Yamada S, et al.Experimental tongue carcinoma of rats induced by oral administration of 4-nitroquinoline 1-oxide (4NQO) in drinking water[J]. Oral Surg Oral Med Oral Pathol, 1985, 59(6): 600-607.
[11] Hawkins BL, Heniford BW, Ackermann DM, et al.4NQO carcinogenesis: a mouse model of oral cavity squamous cell carcinoma[J]. Head Neck, 1994, 16(5): 424-432.
[12] Makita H, Tanaka T, Fujitsuka H, et al.Chemoprevention of 4-nitroquinoline 1-oxide-induced rat oral carcinogenesis by the dietary flavonoids chalcone, 2-hydroxychalcone, and quercetin[J]. Cancer Res, 1996, 56(21): 4904-4909.
[13] Bi Y, Deng J, Murry DJ, et al.A whole-body physiologically based pharmacokinetic model of gefitinib in mice and scale-up to humans[J]. AAPS J, 2016, 18(1): 228-238.
[14] Olson B, Li Y, Lin Y, et al.Mouse models for cancer immunotherapy research[J]. Cancer Discov, 2018, 8(11): 1358-1365.
[15] Nagaya T, Nakamura Y, Okuyama S, et al.Syngeneic mouse models of oral cancer are effectively targeted by anti-CD44-based NIR-PIT[J]. Mol Cancer Res, 2017, 15(12): 1667-1677.
[16] Topalian SL, Taube JM, Anders RA, et al.Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy[J]. Nat Rev Cancer, 2016, 16(5):275-287.
[17] Rothschild U, Muller L, Lechner A, et al.Immunotherapy in head and neck cancer - scientific rationale, current treatment options and future directions[J]. Swiss Med Wkly, 2018, 148: w14625.
[18] Yang Y.Cancer immunotherapy: harnessing the immune system to battle cancer[J]. J Clin Invest, 2015, 125(9): 3335-3337.